Parallax Volatility Advisers, L.P. Clovis Oncology, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $630 - $2,960	-1,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $20,735 - $45,530	-14,500 Reduced 93.55%	1,000 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $56,430 - $99,484	-20,900 Reduced 57.42%	15,500 $42,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $126,671 - $180,960	31,200 Added 600.0%	36,400 $162,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $26,103 - $36,660	5,200 New	5,200 $30,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $94,250 - $275,000	-25,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $512,400 - $1.03 Million	-40,000 Reduced 61.54%	25,000 $372,000
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $2.81 Million - $4.81 Million	-159,000 Reduced 70.98%	65,000 $1.61 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $6.58 Million - $11.1 Million	224,000 New	224,000 $6.58 Million
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $2.51 Million - $3.39 Million	-50,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $1.73 Million - $2.54 Million	30,000 Added 150.0%	50,000 $3.4 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $1.34 Million - $1.7 Million	20,000	20,000 $1.65 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.